Hanmi Science with the gene of 'Innovation'
presented six great visions for the post COVID-19.
Hanmi Science's 6 visions, abbreviated as
'Cydio Cigma', imply key words as 'Cyber Education','Digital Bio','Oral
Bio','City Bio','Green Bio', and 'Marine Bio'. For the vision business, CEO
Chong-Yoon Lim promised toraise outstanding employees’annual salary by 100%
regardless of the ranks.
“Where there is no innovation,
there is no development! Those who shrink from challenges are branded as
cowards ! The cyber education business, digital bio business, oral bio
business, city bio business, green bio business, marine bio business, and Cydio
Cigma are our goals and commitments for the post-COVID-19. ”
These are the 6 great visions of Hanmi
Science unveiled at the 'Tea Time' executive meeting, which is also the
tradition of Hanmi, on the 15th at 7:30 am. The road map of the post-pandemic
era was presented.
Hanmi Pharmaceutical Group has always been
recognized as an innovative company in Korean pharmaceutical bio industry.
Through the equation "Hanmi = R&D", it has become a classic
example of innovation in the pharmaceutical and biological industries, as well
as a symbol of the company that represents the development of new drugs.
Now, the case of Hanmi's innovation and
R&D has gone beyond the development of new drugs, and deviated from the
framework of all existing industries, drawing a blueprint on a blank sheet of
paper. With the mission of combating the post-COVID-19 era, Hanmi, as a leader
of K-Bio, has formulated six visions with Hanmi's macroscopic future
pharmaceutical, bio, and health and welfare solution strategies.
Hanmi Science's 6 great visions, abbreviated
as 'Cydio Cigma', imply key words as 'Cyber Education','Digital Bio','Oral
Bio','City Bio','Green Bio', and 'Marine Bio'. Each item for the six businesses
is Cyber Education, Digital Bio, Oral Bio, City Bio, Green Bio, and Marine Bio.
On this day, CEO Chong-Yoon Lim promised to
change the existing HR resources system by offering 100% annual salary
increases and job titles to those who deliver concrete performance related to
those 6 great visions
Goal & Promise, is a personnel
management system for actualizing management goals of Hanmi, and publicly
proposed to discover talents inside the company that transcend positions to
perform and participate in the 6 vision projects. Hanmi Pharmaceutical Group
(hereinafter referred to as Hanmi) officially declared its macroscopic goals,
changes and wills in order to cope with the post-COVID-19 era.
Launched “Cyber Industry-University
Cooperation Academy” in cooperation with global leading bio-medical
universities
Looking specifically at the six visions
proposed this time, first of all, the framework of "Cyber Education"
is the establishment of K-Bio and K-Med graduate schools, attracting more than
5,000 foreign experts.
Hanmi Science Group has been accumulating
cooperation and joint research courses with overseas medical, bio-related
universities and research institutes over the past few years. It was not a
temporary solution, but rather it’s in line with the most important policy of
R&D in Hanmi Pharmaceutical Group. Starting with a joint research agreement
for public health in Korea-Italy with Catholic Medical School in Rome, Italy
and the Policlinico Universitario Agostino Gemelli in late 2017, CEO Chong-Yoon
Lim established a global research network based on joint research for low birth
rates, neonatal health and postpartum care and other common problems between
Korea and Italy.
Cooperating with Beijing Union Medical
School, which participated as a consortium, he has expanded the concept to fit
China, and is conducting research to suit the characteristics of Korea, China,
and Italy by adding in-depth research on the need for advanced maternal and
child health and the possibility to improve the efficiency of social health
economy through pregnancy management in a country with 20 million newborn
babies.
Hanmi defines Digital Bio
The following is about "Digital
Bio", one of the 6 great visions. Hanmi Science is promoting the 4th
medical industry revolution by combining information and communication
technology and big data through continuous investment in research and development
capabilities. Hanmi Science launches Paltan Smart Plant equipped with a
cutting-edge technologyand unveils the next-generation innovative medical
infrastructure system based on the know-how of Hanmi's electronic distribution
network management system, unmanned prescription system, and hospital
information system over the past 20 years.
Hanmi is not a base for electronics, portals, or online distribution, but is a specialized bio-medical group that has been conducting more than 500 drug developments and clinical trials of more than 30 new bio drugs over 50 years. Currently, various organizations, including the Ministry of Health and Welfare and the U.S. FDA, recognize the importance of participating in such innovative medical systems with verified professional companies.In addition to chronic disease and pregnancy health care, Hanmi is applying for a number of global patents for medical software to cure COVID-19 and is working with the National Institute of Health and Welfare to develop a system that will be applied to the site. Since it can be applied simultaneously in cooperation hospitals in China and Italy, it is expected that such efforts will lead to the positive results of the K quarantine.
Leading the Oral Bio new drug business,
Most domestic new biologics are still
injectables. However, Hanmi, which has developed more than 400 oral medicines,
as a leader in the healthcare/medicine market in the post-COVID-19 era, has the
world's best technology in oral treatment development. This is a completely
differentiating strategy from existing major bio companies based on large
biosimilar (biopharmaceutical generics) factories. In particular, among the
factories owned by Hanmi, Paltan Smart Factory is the world's best smart
factory capable of producing 6 billion tablets annually and 90% unmanned
processes. In addition, Oraxol, which applied the patent platform technology
'Orascovery', transferred technology to Athenex, a US biopharmaceutical company
in 2011, recently announced cases of complete recovery from the most difficult
groups of patients to treat at ASCO, as a result of the recent third-phase
global clinical trial.
Seeing the post-COVID-19 era as a
innovative breakthrough and opportunity, Hanmi unveiled a blueprint for the
next generation of Orascovery. Currently, about 800 new COVID-19 related drugs
are being developed around the world, but new drugs developed as oral or
non-injection drugs are rarely found. It is also considered the most reckless
attempt. But worth it.
The biggest problem under the pandemic
situation is the shortage of medical staff including nursing personnel, the
lack of medical facilities, and the time from treatment development to
commercialization. As an influential treatment for COVID-19 that can overcome
these difficulties, we develop an oral (non-injection) vaccine containing the
next-generation Orascovery technology. "We have already experienced
countless failures and overcomes.
In response to the challenge faced by human
beings called Pandemic, Hanmi will start preclinical trials of "COVID
MDT", the safest and most effective treatment by integrating accumulated
technology and innovative treatment models. There is no more failure than fear
of not challenging," he expressed with confidence.
Signed MOU 'City Bio' with
Gyeongsangbuk-do, Pohang-si and Daegu-Gyeongbuk Free Economic Zone Authority
Hanmi Science leads the creation of Smart
Health care City. Hanmi Science and the Gyeongsangbuk-do, Pohang-si, and
Daegu-Gyeongbuk Free Economic Zone Authority signed an MOU for biomedical smart
city with a business size of about 300 billion won including education, R&D
and manufacturing facilities in Pohang Convergence Technology Industrial Zone
on the 15th. Smart Eco City, which will be unfolded on a green area of 15,000
square meters, is a prototype city that manages life quality from birth to
daily life through a pollution-free bio-environment for all cities and citizens
with "administrative regional medical resource management" suitable
for the post-COVID-19 era.
The computing center, which corresponds to
the brain of this smart city, is a kind of cloud-based solution similar to a
large ERP system designed to enable real-time continuous analysis of biological
activity in the region, citizen health care, medical resource management,
knowledge data base, world-class education, quality of life including food,
exercise, culture, and medical institutionalization of all urban facilities in
case of emergency. In addition, it is equipped with educational facilities
capable of real-time linking to advanced overseas research institutes, so it is
possible to respond to joint research by sharing bio-bank data in medical and
medical situations of world-class medical staff if necessary. As a
post-COVID-19 vision business called City Bio, it will be built as a 'Future
City' that combines the 50-year know-how of the global Hanmi.
Green Bio, applying plant biotechnology,
expanding global healthcare group
Hanmi Science signed a strategic business
agreement with BioApp, a promising venture company in the field of plant
biotechnology in Korea, and promised joint development and joint marketing of
plant-based bio products, also known as "green vaccines," for
domestic and international markets. In particular, the two companies announced
that they will collaborate on the development and commercialization of green
vaccines against various diseases including COVID-19, which is a recent issue.
In addition, the two companies agreed to
establish a joint venture for the overseas sales of the world's first
plant-based swine fever marker vaccine product that has been developed and
commercialized by BioApps, and announced that they would select China as the
first market and proceed with joint venture establishment and product
registration in the near future. This model has received a great deal of
attention from the industry because it is a collaboration between the
outstanding technology of domestic bio companies and Hanmi Science's “Open
Innovation” method, which has already pioneered overseas markets. The two
companies are ultimately drawing a blueprint to challenge Human Madison based
on plant biotechnology.
Hanmi Science signed a technology transfer
contract with Duhu Liu, a professor at the Chinese Academy of Agricultural
Sciences, for a new drug candidate related to metabolic disease, and started
developing a new green bio drug. In order to sign a vision business contract
with China's top bio-biotechnology organization, CEO Chong-Yoon Lim visited
China more than three times to discuss marketability for related technologies
and discuss development roadmaps with the Chinese Academy of Agricultural
Sciences.
Through this agreement, Hanmi Science and
the Chinese Academy of Agricultural Sciences announced that they will jointly
complete the preclinical studies necessary for clinical trials of new drug
candidates, and to work closely with the Beijing Hanmi Research Institute in
the clinical process. According to Hanmi Science officials, in addition to the
candidate materials, it was emphasized that a review of the application of
plant and biotechnology to blockbuster-class pipelines also began inside the
company. Now, Hanmi Science has joined forces with researchers who has the best
green bio technology in both Korea and China to realize the fifth vision of the
post-COVID-19 era to "Revolutionize" the huge production and research
costs of existing bio-new drugs development.
Marine Bio,Open a convergence Marine Bio
Center in Pohang Penta City
Hanmi is looking for a future vision
business in the 'Ocean', which is the original birthplace of living thins on
the Earth, and a bio-bank of all living creatures that preserve the
evolutionary process and covers 70% of the Earth's surface. In other words,
Hanmi Science threw a vote in an unfamiliar area called Marine Bio. This is a
vision project for understanding, protecting, preserving of marine bio
resources,where 80% of the world's species are inhabited but commercial
utilization is less than 1% and researching new drug development mechanisms and
deriving lead materials. In 2004, the pain reliever Prialt, which was created
using the toxicity of sea snails, was reported to have generated $27 million in
sales in 2017, while the black beach sponges-based anti-cancer drug, developed
in Japan and approved FDA in 2010, generated $3.6 billion worldwide in 2017.
With the marine bio industry expected to
grow into a market worth about $8.05 billion by 2030, given the domestic
situation focused on the aquatic food processing industry, Hanmi Science's
Marine Bio Vision business is a roadmap to bring Korea back into the ocean
power. In particular, Pohang is the best place to have the best conditions for
the location of marine resources, with the long history of proving it, and the
fourth generation of accelerators. Through marine bio research, it is possible
to study the underlying biological mechanisms by studying genomic studies
before and after evolution, understanding of the inter-microbial ecosystem of
viruses, and the origin of human cell functions. Hanmi's Marine Bio Center is
expected to be the Noah's Ark of the marine life system.
